22 results
SC14D9C
EX-2.1
PNT
POINT Biopharma Global Inc.
3 Oct 23
Written communication relating to third party tender offer
7:37am
, standards for the manufacture, processing, packaging, testing, transportation, handling and holding of drug products, as set forth in the FDCA
8-K
EX-2.1
PNT
POINT Biopharma Global Inc.
3 Oct 23
Tender and Support Agreement
7:35am
, standards for the manufacture, processing, packaging, testing, transportation, handling and holding of drug products, as set forth in the FDCA
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping … must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected
424B3
568yke0cm5y
31 Mar 22
Prospectus supplement
11:42am
POS AM
44zmx2gt stumn2
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
EX-10.1
42quxo8
12 Nov 21
Prospectus supplement
8:41am
424B3
ecfa2wqp4m1ipj3hfkm
5 Aug 21
Prospectus supplement
4:26pm
424B3
iwbpnni
9 Jun 21
Prospectus supplement
4:42pm
S-4/A
9ufqwg9c
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
EX-10.19
s0x3kndt955 b7c
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
EX-10.14
pelsn6
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4
EX-10.14
mep44m
22 Mar 21
Registration of securities issued in business combination transactions
9:52pm